COMPASS Pathways, Inc. announced it will be conducting a Phase II clinical trial to assess the safety and tolerability of COMP360 psilocybin therapy in post-traumatic stress disorder.
[COMPASS Pathways, Inc.]
7992332
{7992332:nan}
apa
50
1
168571
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
